ANN ARBOR, Mich., September 25, 2025 — Cayman Chemical, a global provider of life science research tools, and Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, have entered a strategic distribution partnership aimed at accelerating innovation in cell and gene therapy development. Under this agreement, Cayman will distribute Akadeum’s portfolio of buoyant microbubble cell isolation kits, bringing this next-generation technology to researchers worldwide.
Science Significance
The partnership introduces Akadeum’s groundbreaking microbubble-based cell isolation platform to Cayman’s extensive catalog of research products. This technology represents the first new cell separation modality in more than 40 years, offering a method that is faster, gentler, and more scalable than conventional techniques like magnetic beads or flow cytometry. By allowing researchers to isolate highly pure cell populations without compromising cell health, this platform enhances early-stage workflows critical for cell and gene therapy development, cancer immunotherapy, and regenerative medicine.
Akadeum’s microbubbles enable cells to be separated through flotation rather than mechanical or magnetic forces, significantly reducing stress on the cells and maintaining high recovery, viability, and superior cell health. Such innovation ensures that therapeutic cell populations remain functional, improving the downstream success rates of gene-edited treatments and adoptive cell therapies.
Regulatory Significance
While the Akadeum kits distributed by Cayman are for Research Use Only (RUO), their integration into preclinical and translational research workflows is an important precursor to eventual clinical applications. This partnership aligns with growing regulatory focus on advanced cell processing technologies that ensure consistency, scalability, and quality—critical factors as more cell and gene therapies approach FDA approval and commercial deployment. By enabling higher-quality starting materials, the technology indirectly supports regulatory compliance in the long term by fostering reproducible results in early research phases.
Advertisement
Business Significance
Cayman Chemical, known for its high-quality biochemicals, assay kits, antibodies, and analytical services, gains a significant competitive advantage by adding Akadeum’s proprietary microbubble technology to its distribution network. This agreement strengthens Cayman’s position as a global leader in life science research tools, broadening its reach into the fast-growing cell and gene therapy market. For Akadeum, the collaboration provides immediate access to Cayman’s global customer base and logistics infrastructure, accelerating commercialization and adoption of its breakthrough platform.
Brandon McNaughton, Ph.D., Akadeum’s CEO and Founder, emphasized, “Through this partnership, scientists worldwide will have access to Akadeum’s microbubble technology, which provides a simpler, more effective method of cell separation that enhances purity, recovery, viability, and scalability.”
Patients’ Significance
For patients, the ripple effects of this collaboration are profound. By streamlining the research process and improving the quality of isolated cells, therapies for cancer, rare diseases, and genetic disorders can move more rapidly from laboratory to clinic. Better cell health at the research stage translates into safer, more effective cell and gene therapies, potentially shortening development timelines and reducing costs for future treatments.
Policy Significance
The Cayman–Akadeum partnership highlights the critical role of domestic innovation and partnerships in strengthening the cell and gene therapy ecosystem. As governments and regulatory agencies push for greater supply chain resilience and advanced manufacturing capabilities, this agreement showcases how collaborations can expand access to cutting-edge technologies while supporting public health priorities and national competitiveness in biomedical research.
Transaction Highlights
Under the new agreement, Cayman Chemical will distribute Akadeum Life Sciences’ buoyant microbubble cell isolation kits through its global research network, bringing this next-generation technology to laboratories worldwide. Developed and manufactured at Akadeum’s Ann Arbor, Michigan headquarters, the microbubble-based platform represents the first new cell separation modality in more than four decades, offering a faster, gentler, and more scalable solution compared to traditional magnetic or column-based methods. By integrating these innovative kits into Cayman’s extensive life science portfolio, the partnership aims to overcome long-standing challenges in isolating highly pure cell populations, delivering improved recovery rates, high viability, and superior cell health. This collaboration not only strengthens Cayman’s position as a trusted supplier of advanced research tools but also accelerates global access to cutting-edge technologies critical for cell and gene therapy development, regenerative medicine, and diagnostics.
Source: Cayman Chemical Press Release
